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Background: Juvenile idiopathic arthritis-associated uveitis (JIA-U) can lead to poor visual outcomes and impact a
child’s quality of life (QOL) and function. Our aim is to identify risk markers of JIA-U and examine differences in the
QOL of children with JIA and JIA-U.
Methods: Rheumatology and ophthalmology record reviews and questionnaires were completed every 4–6
months on 287 children with JIA. We collected arthritis, uveitis, and QOL data. We examined data through last
study visit.
Results: There were 52/287 (18 %) children with JIA-U who were younger at arthritis diagnosis, had oligoarticular
persistent JIA, and ANA positive. Confirmed uveitis predictors were age at JIA diagnosis (OR = 0.86) and oligoarticular
subtype (OR = 5.92). They had worse vision specific QOL and function, but similar general QOL. Blindness occurred in
17.5 % of children but was more common in African American children compared to non-Hispanic Caucasian children
((5/7 (71 %) vs. 2/29 (7 %), p <0.001) despite a similar uveitis prevalence (22 % vs. 16 %). Both races had similar
complications, although band keratopathy was more frequent in African Americans (75 % vs. 15.6 %, p = 0.003).
Conclusions: We confirm young age at JIA diagnosis and the oligoarticular JIA subtype as predictors of uveitis
development. Although we were unable to identify predictors of ocular complications or blindness, AA children
appeared to have a more severe disease course manifested by increased ocular complications, vision loss and
blindness. Potential causes that warrant additional study include underlying disease severity, access to medical
care and referral bias. Further investigation of the risk factors for vision-compromising uveitis and its’ long-term
effects should be conducted in a large racially diverse population.
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Juvenile idiopathic arthritis-associated uveitis (JIA-U)
can lead to ocular complications and permanent vision
loss. Approximately 10-25 % of the 300,000 children in
the United States with JIA develop uveitis within the
first 4 years of their arthritis diagnosis [1–8]. JIA-U is an
anterior, non-granulomatous chronic inflammatory ocu-
lar disease that is frequently asymptomatic at onset.* Correspondence: sangele@emory.edu
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unless otherwise stated.Vision loss and ocular complications have been reported
in 3-66 % of children [9, 6, 10–13, 3, 2]. These devastat-
ing ocular sequelae may be prevented by identifying chil-
dren at greatest risk for severe disease.
The American Academy of Pediatrics guidelines rec-
ommend ophthalmology screening every 3–4 months in
children with oligoarticular or polyarticular rheumatoid
factor (RF) negative arthritis who are antinuclear anti-
body (ANA) positive, <7 years of age, and diagnosed
with arthritis for ≤4 years since they are at high risk for
developing uveitis [14]. These factors have been con-
firmed in several studies [14, 5, 15–17, 11, 9]. Risk fac-
tors for vision loss and/or ocular complications includeentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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diagnoses, a uveitis diagnosis prior to arthritis diagno-
sis, young age at uveitis onset, an anterior chamber cell
score ≥1+, initial visual acuity (VA) of 20/200 or worse,
and presence of complications at first ophthalmology
examination [18–21]. Hence, early detection of ocular
disease and timely aggressive treatment in high risk pa-
tients can prevent poor visual outcomes.
Our primary objective is to identify risk markers for uve-
itis development and a severe ocular course in children
with JIA by (1) comparing those with JIA alone and those
with JIA-associated-uveitis (JIA-U), and (2) analyzing chil-
dren with severe uveitis. We defined severe disease as a
history of ocular complications, vision loss (VA 20/50 or
worse) and legal blindness (VA 20/200 or worse).
Methods
This is a retrospective analysis of prospectively collected
data. It was approved by the Institutional Review Board of
Emory University and conformed to the requirements
of the US Health Insurance Portability and Privacy Act.
Informed consent was obtained from the parent/legal
guardian, and assent was obtained from the children if
applicable. Research adhered to the tenets of the Dec-
laration of Helsinki.
Subjects
Eligible children presenting with a diagnosis of JIA or
uveitis were enrolled from the pediatric rheumatology
outpatient clinics from November 2011 to January 2015.
They were followed prospectively from time of enroll-
ment and returned for their usual follow up appoint-
ment every 3–6 months. Inclusion criteria included: 1) a
diagnosis of JIA with or without uveitis and 2) English
speaking. Exclusion criteria included: 1) a diagnosis of
another chronic or autoimmune disease associated with
uveitis; 2) major developmental disorders (i.e. cerebral
palsy, autism); 3) other chronic disorders that can affect
quality of life (QOL) and function; and 4) refusal to par-
ticipate. Some patients were diagnosed with JIA or uve-
itis months or years prior to enrollment.
Data collection
We reviewed rheumatology and ophthalmology medical
records from time of presentation to every 3–6 months
during the usual pediatric rheumatology follow up visit.
Baseline data collected included date of birth, gender, par-
ents self-described race and ethnicity, arthritis characteris-
tics (onset, date of diagnosis, JIA subtype, joints with
tenderness swelling and/or limitation, radiographs), uveitis
characteristics (onset, date of diagnosis, laterality, location,
ocular complications, surgeries), ocular exam (best cor-
rected visual acuity (VA), intraocular pressure, anterior
chamber cells and flare), labs (ANA, RF, erythrocytesedimentation rate (ESR), HLA-B27, and anti-cyclic citrul-
linated peptide (anti-CCP)) and all medications used cur-
rently and in the past. Follow up data on arthritis, uveitis,
labs and medications were collected at 3–6 month inter-
vals (time of last study visit to current study visit) and dur-
ing uveitis flares. Data from the ocular exam was recorded
from every ophthalmology visit with varied intervals de-
pending on presence of uveitis and disease activity.
Measures of quality of life and function
We administered parent- and patient-based question-
naires at each study visit - the Childhood Health Assess-
ment Questionnaire (CHAQ) to measure physical
function, the Pediatric Quality of Life Inventory Version
4.0 (PedsQL) to measure overall QOL, and the Effects of
Youngsters Eyesight on Quality of Life (EYE-Q) to meas-
ure vision related QOL and function [22–25]. Child-
report forms were administered as appropriate per age
based on the specific measure. Questionnaires were read
by the study team to children who had significant visual
impairment.
The CHAQ evaluates functional disability and has
well-documented reliability and validity [22]. There are
20 questions encompassing 8 functional components: 1)
dressing and grooming, 2) arising, 3) eating, 4) walking,
5) hygiene, 6) reach, 7) grip, and 8) activities. There are
three parameters within each area: 1) difficulty in per-
forming daily functions, 2) use of special aids or devices,
and 3) activities that require assistance from another
person. Scores range from 0 to 3 and lower scores indi-
cate better physical function.
The PedsQL is a validated measure of health-related
QOL in children and adolescents from 2 to 18 years of
age [23]. Four core scales are measured on a 5-point-
scale: 1) physical functioning (8 items), 2) emotional
functioning (5), 3) social functioning (5), and 4) school
functioning (5). Scores range from 0–100 with higher
scores indicating better QOL. For this study, we in-
cluded measures of overall QOL (PedsQL Total) and
psychosocial related QOL (PedsQL Psychosocial).
The EYE-Q is a measure of vision related QOL and
function in children [25, 24, 26]. It consists of both parent
and patient self-reports for children 5–18 years old. There
are 19 items that query on tasks that rely on distance,
near, color, and night vision; functionality; and photosensi-
tivity. QOL items inquire about feelings regarding medica-
tion use, missing school, and lab draws using a 5-point
Likert scale response format. There is a question about
ocular symptoms, the use of visual aids, and a subjective
assessment of vision severity.
Statistical analysis
Statistical analyses were conducted using SAS v9.3 for
Windows (Cary, NC). Statistical significance was assessed
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rized using means and standard deviations, medians and
interquartile ranges (25th – 75th percentile) or counts and
percentages, when appropriate. Duration of arthritis and/or
uveitis were calculated as time between date of diagnosis to
last study visit. Duration between uveitis and arthritis
diagnosis was calculated by subtracting date of arthritis
diagnosis from date of uveitis diagnosis. We compared
children with JIA alone and JIA-associated uveitis using
Chi-square tests and two sample t-tests. In instances of
small expected cell counts (<5), exact Chi-square tests
were used. When continuous data were skewed or non-
normal, a nonparametric test (Mann Whitney-U or
Kolmogorov-Smirnov test) was used in place of the two
sample t-test.
We conducted further analysis in children with uveitis
and compared those with and without ocular complica-
tions, those with a VA of 20/200 and worse, and African
American (AA) and Caucasian (W) children with uveitis.
Subgroups (i.e., complicated vs. uncomplicated, vision
loss vs. no vision loss, AA vs. W) were compared using
similar methodology described above. Multivariable lo-
gistic regression was used to simultaneously model mul-
tiple risk factors for development of uveitis. Similar
models were constructed for the outcome of compli-
cated disease. Candidate predictors identified in the uni-
variate analyses were entered into the model. Stepwise
backward elimination was used to obtain the final
model. Non-significant variables were systematically re-
moved until all variables in the model were significant at
the 0.05 level or a significant reduction in model fit was
observed.Results
Demographics and clinical characteristics of cohort
There were 287 children with JIA of whom 52 (18 %)
had uveitis at the last study visit (Table 1). Of the 52
children with uveitis, 5 with JIA alone developed uveitis
after enrollment, and 1 child with uveitis alone devel-
oped JIA. Our cohort consisted of 71 % females,
77 % W, and 12 % AA children. The median (IQR) age
of arthritis diagnosis was 6.4 years (2.9 – 11.7), and 41 %
were of the oligoarticular persistent JIA subtype.Characteristics of children with uveitis
Children with uveitis were primarily female (77 %), and
73 % were W, 15 % were AA, and of these, 15 % were
also Hispanic. Most had anterior uveitis (80 %), bilateral
involvement (72 %) and several ocular complications
(cataracts (31 %), synechiae (31 %), band keratopathy
(25 %), glaucoma (17 %), and cystoid macular edema
(15 %)). They were diagnosed with arthritis at a median
of 2.8 years of age and uveitis at 4.8 years of age.In comparing children with JIA alone vs those with JIA-
U (Table 1), more children with JIA-U had oligoarticular
persistent JIA (75 % vs. 34 %, p < 0.001), were significantly
younger at arthritis diagnosis (2.8 vs. 7.7 years, p < 0.001),
ANA positive (55 % vs. 36 %, p = 0.017), rheumatoid factor
negative (0 % vs. 11 %, p = 0.013) and anti-CCP negative
(0 % vs. 10 %, p = 0.020). They were less likely to be of the
polyarticular RF negative (p = 0.049) and systemic JIA sub-
types (p = 0.038).
On sub-analysis, we then considered 91 children who
had JIA for ≥4 years since approximately 80 % of the cases
of uveitis in children with JIA are diagnosed within 4 years
of JIA diagnosis. Even after restricting the analyses to this
subgroup, those with uveitis were still likely to be younger
at arthritis diagnosis (p < 0.001), have oligoarticular per-
sistent JIA (p <0.001), be RF negative (p = 0.026) and be
anti-CCP negative (p = 0.026). The associations between
ANA positivity, and the other JIA categories were no lon-
ger significant.
In comparing males and females with uveitis, fe-
males were younger at arthritis and uveitis diagnosis
(2.3 years vs. 6.6 years, p = 0.002, and 4.5 years vs.
7 years, p = 0.017) and ANA positive (66.7 % vs.
16.7 %, p = 0.003). There were no differences in ocu-
lar complications or medication use.
Forty-five percent of children had vision loss, 50 %
had at least one ocular complication, and 17 % (8/47)
had a history of legal blindness. Of these 8 children,
only one had a history of bilateral blindness. There
were no significant differences in clinical characteris-
tics based on the presence of mild vision loss (VA
20/50 or worse) (N = 26 vs. 20); however AA had
more vision loss compared to W (6/7 (86 %) vs. 13/
35 (37 %), p = 0.018) (data not shown).Vision loss was
associated with higher rates of complications: cataract
(p < 0.001), band keratopathy (p < 0.001), cystoid macular
edema (p = 0.015) In addition, those with vision loss re-
quired the use of more anti-tumor necrosis factor agents
(p = 0.042) . Comparing children with and without ocular
complications (N = 26 vs. 26), those with complications
had more blindness (0 % vs. 33.3 %, p = 0.002), and a his-
tory of steroid ocular injections (3.9 % vs. 36 %, p = 0.005).
Children with a history of legal blindness (VA of 20/200 or
worse) (N = 8) were primarily non-Hispanic (18 % vs. 0 %,
p = 0.017), AA (62.5 % vs. 5.1 %, p < 0.001) and had signifi-
cantly more ocular complications (i.e. cataracts (p < 0.001),
glaucoma (p < 0.001), synechiae (p = 0.040), band keratop-
athy (p < 0.001), and cystoid macular edema (p < 0.001)),
cataract extractions (p = 0.026), and intraocular steroid in-
jections (p = 0.001).
Predictors of uveitis development
On univariate analysis, oligoarticular persistent JIA sub-
type, ANA positivity, age at arthritis diagnosis, and anti-
Table 1 Characteristics of Children with JIA and JIA-associated Uveitis
Characteristics Group
Median (25th – 75th) unless otherwise specified Overall (N = 287) JIA (N = 235) JIA-U (N = 52) P-value
Demographics
Gender, female, N (%) 205 (71.4 %) 165 (70.2 %) 40 (76.9 %) 0.332
Hispanic, N (%) 24 (8.4 %) 16 (6.8 %) 8 (15.4 %) 0.043*
Race, N (%)
Caucasian 221 (77.0 %) 183 (77.9 %) 38 (73.1 %) 0.459
African American 36 (12.5 %) 28 (11.9 %) 8 (15.4 %) 0.500
Other 30 (10.5 %) 24 (10.2 %) 6 (11.5 %) 0.800
Disease Characteristics
Age JIA diagnosis (yrs.) 6.4 (2.9 – 11.7) 7.7 (3.8 – 12.0) 2.8 (1.8 – 6.6) <0.001*
Duration of JIA at last study visit (yrs.) 3.4 (1.8 – 5.9) 3.1 (1.6 – 5.3) 5.6 (2.9 – 8.9) <0.001*
Total follow up time (months, mean ± SD) 15.1 ± 12 14.2 ± 11.7 18.8 ± 12.7 0.012*
JIA subtype, N (%)
Oligo persistent 119 (41.1 %) 80 (34.0 %) 39 (75.0 %) < 0.001*
Oligo extended 14 (4.9 %) 12 (5.1 %) 2 (3.9 %) 0.754
Polyarticular RF (−) 70 (24.4 %) 63 (26.8 %) 7 (13.5 %) 0.049*
Polyarticular RF (+) 13 (4.5 %) 13 (5.5 %) 0 (0.0 %) 0.135
Systemic 22 (7.7 %) 22 (9.4 %) 0 (0.0 %) 0.038*
Psoriatic 10 (3.5 %) 10 (4.3 %) 0 (0.0 % 0.217
Enthesitis related 37 (12.9 %) 33 (14.0 %) 4 (10.8 %) 0.260
Undifferentiated 2 (0.7 %) 2 (0.9 %) 0 (0.0 %) 1.00
Labs, N (%)1
ANA (+) (n = 286) 112 (39.3 %) 84 (35.9 %) 28 (54.9 %) 0.017*
RF (+) (n = 288) 26 (9.1 %) 26 (11.1 %) 0 (0.0 %) 0.013*
Anti-CCP (+) (n = 285) 24 (8.5 %) 24 (10.3 %) 0 (0.0 %) 0.020*
HLA-B27 (+) (n = 192) 32 (16.8 %) 26 (16.3 %) 6 (18.8 %) 0.740
Earliest ESR (n = 283) 16 (6 – 38) 14.5 (6 – 38) 22 (8 – 38) 0.327
Medication Use, N (%) (n = 287)
Methotrexate oral 160 (55.9 %) 124 (52.8 %) 36 (70.6 %) 0.020*
Methotrexate injection 167 (58.4 %) 129 (54.9 %) 38 (74.5 %) 0.010*
Infliximab 38 (13.3 %) 21 (8.9 %) 17 (33.3 %) < 0.001*
Etanercept 48 (17.0 %) 45 (19.4 %) 3 (5.9 %) 0.022*
Adalimumab 64 (22.4 %) 52 (22.1 %) 12 (23.5 %) 0.828
Abatacept 6 (2.1 %) 4 (1.7 %) 2 (3.9 %) 0.600
Quality of Life Scores (child)a
PedsQLb Total 79.9 (66.5 – 90.2) 80.3 (66.5 – 90.2) 78.6 (66.2 – 90.7) 0.612
PedsQLb Psychosocial 81.0 (67.2 – 90.3) 81.9 (69.4 – 90.5) 76.2 (65.0 – 89.7) 0.248
CHAQc 0.25 (0.04 – 0.66) 0.25 (0.04 – 0.66) 0.25 (0.04 – 0.88) 0.690
EYE-Qd 3.62 (3.38 – 3.82) 3.68 (3.46 – 3.84) 3.35 (2.88 - 3.56) < 0.001*
Quality of Life Scores (parent)a
PedsQLb Total 81.7 (66.3 – 90.7) 81.8 (65.6 – 89.7) 81.3 (69.2 – 92.5) 0.679
PedsQLb Psychosocial 82.5 (67.9 – 92.5) 81.2 (68.1 – 92.3) 82.4 (67.1 – 92.6) 0.933
CHAQc 0.25 (0.04 – 0.63) 0.31 (0.06 – 0.67) 0.15 (0 – 0.49) 0.091
EYE-Qd 3.73 (3.48 – 3.86) 3.75 (3.55 – 3.88) 3.41 (3.20 – 3.64) < 0.001*
aIndicates missing data; *p = <0.05; bPediatric Quality of Life Inventory; cChildhood Health Assessment Questionnaire; dEffects of Youngsters Eyesight on Quality
of Life
Chi-square tests, two sample t-tests, non-parametric test (Mann Whitney-U or Kolmogorov-Smirnov test)
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opment (Table 2). On multivariate analysis, age at arth-
ritis diagnosis (OR = 0.91; 95 % CI [0.84 – 0.99] and
oligoarticular JIA subtype remained significant (OR =
4.64; 95 % CI [2.21 – 9.75]) and were the best combin-
ation of predictors of uveitis among the models we con-
sidered (AUC = 0.77).
Quality of life and function
Children with uveitis had worse vision related QOL and
function compared to children with JIA alone as mea-
sured by the EYE-Q child and parent reports (p < 0.001)
(Table 1). However, all children had similar overall QOL,
psychosocial QOL and physical function as measured by
the PedsQL and CHAQ.
Medication use
Most children with uveitis were treated with subcutane-
ous and/or oral methotrexate (85 %). Of the 8 patients
who had never been on methotrexate (15 %): 1 has only
used NSAIDS; 6 have taken NSAIDs and steroid eye
drops; and 1 has only taken steroid eye drops. For those
who were refractory to methotrexate, 33 % of children
with uveitis were treated with infliximab and 24 % were
treated with adalimumab. Children with vision loss and
blindness were treated mainly with infliximab (p = 0.014,
p = 0.022, respectively). There was no significant differ-
ence in the use of methotrexate, infliximab, etanercept,
adalimumab or abatacept in children with and withoutTable 2 Discriminatory Power of Single Risk Factors for JIA-U vs. Mu
Model Risk factor
Univariate Models
Oligoarticular Persistent Subtype –
ANA Positivity –
Age Arthritis Diagnosis (per 1 year increase) –
AA Race vs. NHW –
Anti-CCP negative –
Multivariable Models Risk Factor
Oligo. PEa + Age Arthritis Diagnosis Oligo PEa
Age
Oligo PEa + ANA Positivity Oligo PEa
ANA +
Oligo PEa + Large Joints Oligo PEa
Large Joint
Age Arthritis Diagnosis + ANA Positivity Age
ANA +
Age Arthritis Diagnosis + ANA Positivity + Oligo PEa Age
ANA +
Oligo PEa
aOligoarticular Persistent JIA subtype; Multivariable logistic regressionocular complications, or in AA and W children with
uveitis. All children may have been on ≥1 medication.
Of the 44 children treated with methotrexate and/or a
biologic, 12 (27 %) developed uveitis during treatment. Of
the 12, 10 developed uveitis while on methotrexate, 1 de-
veloped uveitis after discontinuing methotrexate (within
6 months) but on abatacept, and 1 while on both metho-
trexate and adalimumab. The majority (70 %) started
methotrexate after their uveitis diagnosis.
Epidemiology of uveitis
In our 52 children with uveitis, we had data on time to
uveitis diagnosis in 50 patients in relation to arthritis
diagnosis (Table 3). Approximately 24 % of children
were diagnosed with uveitis prior to JIA, and 22 %
within the 1st year of their JIA diagnosis. Cumulatively,
86 % of children were diagnosed with uveitis within
4 years of their JIA diagnosis, and 4 % by 5 years.
Children with uveitis compared by race
In examining our data on the 8 children with legal blind-
ness (VA of 20/200 or worse), we noted an increased fre-
quency of AA children (5/7 (71 %) with a blind outcome
compared to W children (2/29 (7 %)) despite a similar
uveitis prevalence (22 % vs. 16 %) when restricting to
non-Hispanic Caucasians and excluding children with
missing data (Table 4). Although our results on race are
underpowered due to a small number of AA children
with uveitis, we conducted sub-analysis to compare AAltiple Risk Factors
Odds ratio 95 % CI AUC
5.92 (2.99 – 11.74) 0.71
2.13 (1.15 – 3.92) 0.59
0.86 (0.80 – 0.93) 0.71
1.56 (0.65 – 3.74) 0.57
– – 0.55
Odds Ratio 95 % CI AUC
4.64 (2.21 – 9.75) 0.77
0.91 (0.84 – 0.99)
5.30 (2.65 – 10.60) 0.73
1.65 (0.86 – 3.15)
5.39 (2.64 – 11.01) 0.72
s 1.53 (0.62 – 3.79)
0.87 (0.81 – 0.94) 0.71
2.05 (1.08 – 3.90)
0.92 (0.85 – 1.00) 0.76
1.82 (0.94 – 3.54)
4.17 (1.97 – 8.83)
Table 3 Uveitis diagnosis in relation to Arthritis JIA diagnosis
Diagnosis time Na = 50 Cumulative %
Prior to JIA Diagnosis 12 (24.0 %) 12 (24.0 %)
Within 1 year of JIA Diagnosis 11 (22.0 %) 23 (46.0 %)
Within 2 years of JIA Diagnosis 10 (20.0 %) 33 (66.0 %)
Within 3 years of JIA Diagnosis 5 (10.0 %) 38 (76.0 %)
Within 4 years of JIA Diagnosis 5 (10.0 %) 43 (86.0 %)
Within 5 years of JIA Diagnosis 4 (8.0 %) 47 (94.0 %)
More than 5 years 3 (6.0 %) 50 (100 %)
aN = 2 Missing
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itis has rarely been explored. AA children were signifi-
cantly older at uveitis diagnosis (11.3 years vs. 4.6 years,
p = 0.033), and had an increased history of a VA of 20/
200 or worse (71.4 % vs. 6.9 %, p < 0.001) and band ker-
atopathy (75 % vs. 15.6 %, p = 0.003). They appeared to
have more ocular complications, and upon further
examination, AA had on average 3 times as many com-
plications as NHW (p < 0.001). There were no differ-
ences in insurance status, age at arthritis diagnosis, JIA
subtypes, duration between uveitis and arthritis diagno-
ses, treatment, or QOL.
Table 5 examines the characteristics of the 8 AA chil-
dren with uveitis based on age of JIA diagnosis. Four
children were diagnosed with JIA at <7 years of age
(AAP cut off age for frequent ocular examinations) of
whom three were diagnosed with uveitis within 4 years
of arthritis. They had a history of a VA of worse than 20/
200 and ocular complications. The four that were diag-
nosed with JIA ≥7 years of age had uveitis either at pres-
entation or prior to a JIA diagnosis and three had better
VA and less complications. The one child diagnosed at
7 years of age had disease that was similar to the youn-
ger group, and it is possible she had an earlier onset that
was unrecognized.
Discussion
Our study confirms known risk factors associated with
uveitis development in children with JIA– young age at
JIA diagnosis, oligoarticular JIA subtype, ANA positivity,
RF negativity and anti-CCP negativity; only the oligoarti-
cular JIA subtype and young age at arthritis diagnosis
remained significant predictors in our model [6, 27, 12].
When analysis was restricted to children at lower risk
for uveitis (a diagnosis of JIA >4 years), these two pre-
dictors remained significant. We also confirm reports
that most children are diagnosed within the first 4 years
of arthritis (86 %), hence regular screening within the
first 4 years of a JIA diagnosis is crucial. We were unable
to identify predictors of severe uveitis (increased ocu-
lar complications, blindness) and found no significantdifferences in gender, duration between arthritis and
uveitis diagnoses, age at uveitis onset, and a uveitis
diagnosis prior to arthritis diagnosis in children with
severe disease.
Uveitis can have a negative impact on a child’s daily
function and ability to perform visual tasks in the home
and school [28]. Additionally, children need regular
ophthalmology and rheumatology physician visits, phle-
botomy, frequent ophthalmic drops, and systemic im-
munosuppressive therapy consisting of oral medications,
injections and infusions. Investigation into the effects of
uveitis on a child’s QOL and function is important. Most
studies use general QOL measures, arthritis specific
measures, and the ocular exam as a measure of out-
come. The EYE-Q is the only patient reported outcome
measure specific to uveitis which we are currently valid-
ating in a pediatric uveitis population [24, 25]. In our co-
hort, children with uveitis appeared to suffer from worse
vision specific function and QOL but no differences
were apparent in general QOL or physical function. We
expected those with both JIA and uveitis to experience
worse general QOL due to involvement of two systems.
It is possible that any diagnosis of chronic autoimmune
disease affects QOL equally since care and treatment are
similar, irrespective of number of diagnoses and disease
activity. This emphasizes the importance of a global and
comprehensive assessment of outcomes that takes into
consideration vision specific measures, and not limited
to general measures.
Race can be associated with various autoimmune con-
ditions, including JIA and systemic lupus erythematosus.
In JIA, more children of European descent develop oli-
goarticular disease, whereas non-European children de-
velop polyarticular rheumatoid factor (RF) positive JIA
with worse arthritis outcomes [29–31]. Since JIA sub-
types differ in their association with uveitis, and race
predisposes to different JIA categories, race may influ-
ence uveitis risk.
Few studies describe the association of race with
pediatric uveitis. In adults, the Pacific Ocular Inflamma-
tion Study noted that of 224 uveitis cases, 38 % were
Asian, 37 % were white, and only 2 % were Black [32].
However, Blacks had the highest incidence of uveitis at
39.6 cases per 100,000 patient years. In a JIA cohort in
Toronto, the incidence of uveitis was similar in children
of European and non-European ancestry (14.4 % vs.
12.8 %) although when compared to the general Toronto
population, risk was increased in European children and
decreased in non-European ancestries [29].
Uveitis has been reported in approximately 6-8 % of
AA children with JIA and ANA positivity varies al-
though other reports no associations with race (Table 6)
[33, 34, 29, 16, 35]. In our cohort, uveitis frequency was
similar in AA and W children (22 % vs. 17 %), with only
Table 4 Comparison of African American and Caucasian Children with JIA-associated Uveitis
Characteristics Race P-value
Median (25th – 75th) unless otherwise specified AA (N = 8) NHW (N = 32)
Demographics
Age at last study visit 16.3 (10.0 – 17.5) 8.5 (6.7 – 12.4) 0.024
Gender, female, N (%) 5 (62.5 %) 24 (75.0 %) 0.660
Insurance- Private, N (%) 3 (37.5 %) 21 (66.6 %) 0.147
JIA Disease Characteristics
Age at arthritis diagnosis (yrs.) 3.4 (2.5 – 16.5) 2.8 (1.7 – 5.0) 0.172
Duration of JIA at last study visit (yrs.) 5.7 (2.0 – 14.0) 5.6 (3.0 – 8.9) 0.881
JIA Subtype, N (%)
Oligoarticular persistent 4 (50.0 %) 26 (81.3 %) 0.089
Polyarticular rheumatoid factor (−) 3 (37.5 %) 4 (12.5 %) 0.128
Enthesitis related arthritis 1 (12.5 %) 2 (6.3 %) 0.498
Uveitis Disease Characteristics
Age at uveitis diagnosis (yrs.) 11.3 (4.6 – 14.5) 4.6 (3.4 – 6.8) 0.033*
Duration of uveitis at last study visit (yrs.) 4.4 (3.2 – 7.2) 3.4 (1.3 – 7.1) 0.395
Duration between uveitis and arthritis diagnosis (yrs.) 1.3 (−1.2 – 4.0) 1.3 (0 – 2.4) 0.970
Location of disease, N (%)a 1.00
Anterior 5 (83.3 %) 23 (79.3 %)
Unknown 1 (16.7 %) 6 (20.7 %)
Bilateral disease, N (%)a 6 (75.0 %) 19 (70.4 %) 1.00
Visual acuity worse than 20/200 5 (71.4 %) 2 (6.9 %) 0.001
Type of Complications, N (%)
Cataracts 5 (62.5 %) 9 (28.1 %) 0.102
Glaucoma 3 (37.5 %) 4 (12.5 %) 0.128
Synechiae 4 (50.0 %) 8 (25.0 %) 0.211
Band keratopathy 6 (75.0 %) 5 (15.6 %) 0.003*
Cystoid macular edema 3 (37.5 %) 4 (12.5 %) 0.128
Other complications 3 (37.5 %) 3 (9.4 %) 0.082
Ocular Surgeries, N (%)
Cataract extraction 1 (12.5 %) 2 (6.3 %) 0.498
Steroid ocular injection 2 (25.0 %) 7 (21.9 %) 1.00
Labs, N (%)a
ANA 4 (50.0 %) 18 (56.3 %) 1.00
HLA-B27 0 (0 %) 5 (25.0 %) 0.298
Medication Use, N (%)a
Methotrexate oral 4 (50.0 %) 22 (71.0 %) 0.402
Methotrexate subcutaneous injection 6 (75.0 %) 22 (71.0 %) 1.00
Infliximab 4 (50.0 %) 9 (29.0 %) 0.402
Etanercept 0 (0 %) 3 (9.7 %) 1.00
Adalimumab 1 (12.5 %) 8 (25.8 %) 0.653
Abatacept 0 (0 %) 1 (3.2 %) 1.00
Quality of Life Scores (child)a
PedsQLb Total 73.1 (54.1 – 82.8) 77.5 (67.4 – 90.8) 0.416
PedsQLb Psychosocial 69.6 (56.0 – 83.1) 76.2 (65.0 – 90.0) 0.396
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Table 4 Comparison of African American and Caucasian Children with JIA-associated Uveitis (Continued)
CHAQc 0.27 (0.15 – 0.84) 0.38 (0.04 – 0.88) 0.875
EYE-Qd 2.9 (2.3 – 3.6) 3.3 (3.0 – 3.5) 0.480
Quality of Life Scores (parent)a
PedsQLb Total 69.1 (46.9 – 83.9) 80.3 (71.8 – 92.6) 0.145
PedsQLb Psychosocial 64.3 (51.9 – 80.8) 84.2 (68.2 – 92.6) 0.061
CHAQc 0.51 (0.0 – 1.28) 0.18 (0.0 – 0.45) 0.367
EYE-Qd 2.9 (2.0 – 3.6) 3.4 (3.2 – 3.6) 0.189
aIndicates missing data; *p = <0.05; bPediatric Quality of Life Inventory; cChildhood Health Assessment Questionnaire; dEffects of Youngsters Eyesight on Quality
of Life
Chi-square tests, two sample t-tests, non-parametric test (Mann Whitney-U or Kolmogorov-Smirnov test)
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with our findings in the large Childhood Arthritis and
Rheumatology Research Alliance (CARRA) registry (6 %
vs. 12 %) which consisted of almost 4000 children with
JIA [16]. However, our population may differ due to our
location in the Southeast leading to ascertainment bias.
A 1984 study demonstrated that 8.3 % of 42 South
African children with JIA developed uveitis, but none
were ANA positive [36]. In 1997, of 172 children with
juvenile rheumatoid arthritis (JRA), 20 % were of African
descent, 8.7 % of these had uveitis, and none were ANA
positive [34]. In 2007, 4 % of 758 children with JIA were
of African descent and had a lower risk of developing
JIA-U [29]. In 2010, Adelowo examined 23 children with
JIA and noted that only two (8.6 %) were diagnosed with
uveitis [37]. In 2013, we reported that only 13 of the 220
(5.6 %) AA children in the Childhood Arthritis andTable 5 Characteristics of Children of African Descent with JIA-assoc
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aNegative numbers indicate diagnosis of uveitis prior to JIA; boligoarticular; cpolyartRheumatology Research Alliance (CARRA) registry de-
veloped uveitis and 4 of them were ANA positive [16].
Hence, only small cohorts of AA children with JIA and
uveitis have been examined.
There is less information on the uveitis course of AA
children with JIA, and one study describes severe out-
comes in African children with uveitis secondary to vari-
ous etiologies (idiopathic, Still’s disease, and sympathetic
ophthalmia) [38]. Woreta et. al. report that in their JIA-
U cohort, there were no associations between race and
ocular complications, a VA of 20/50 or worse, or a VA of
20/200 or worse, although they only had 5 blacks and 64
white patients [39]. In our cohort, AA and W children
had similar arthritis characteristics since all AA children
were primarily of the oligoarticular or polyarticular RF
negative JIA subtype, and uveitis was diagnosed within
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Table 6 Comparison of Uveitis Frequency in Various African American (AA) Juvenile Arthritis Population Studies
Study Total children with juvenile arthritis % (N) of AA with
juvenile arthritis
% (N) of AA
with uveitis
% (N) of aa with uveitis who are
ana (+)
Haffejee, 1984 [36] 60 (systemic, oligoa and polyb) 100 % (60) 8.3 % (5) 0 %
Schwartz, 1997 [34] 172 (oligoa and polyb) 20 % (35) 8.7 % (3) 0 %
Adelowo, 2010 [37] 23 (systemic, oligoa and polyb) 100 % (23) 8.6 % (2) 12.4 % (1/8, unknown if uveitis)
Angeles-Han, 2013 [16] 3967 (all JIA) 5.6 % (220) 6 % (13) 44 % (4)
Current cohort 287 (all JIA) 13 % (38) 21 % (8) 50 % (4)
aoligoarticular; bpolyarticular
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complications, vision loss, and blindness. Examining the
characteristics of each AA child with JIA-U, we note that
those diagnosed with JIA at 7 years and younger had a
more severe course, hence, the AAP recommended
screening guidelines are crucial and more frequent mon-
itoring may be important (Table 5). We are unable to as-
certain whether this is secondary to biologic differences
or variances in access to health care. This needs further
study in a large racially diverse multi-center population.
There are otherwise no other reports on the course of
disease in children of African descent.
Strengths and limitations
Our current cohort may not accurately reflect uveitis
prevalence since not all children have had JIA for 4 years
and may still develop uveitis. Thus, longer follow up is
needed, especially in young children with early disease
since they are at highest risk for uveitis. We continue to
follow our cohort prospectively and recruit patients with
newly diagnosed JIA.
Exploration of the association of race with uveitis
should be performed in a larger and more diverse co-
hort, likely in a multi-center study. There appeared to be
differences in uveitis course based on race, but our ana-
lysis was underpowered. However, although our cohort
of AA children is small, the number of those with JIA-U
is similar to previously published reports, including our
analysis of the large CARRA registry which had 13 (6 %)
AA children with uveitis (Table 5). We had an increased
frequency of uveitis compared to other studies, and this
may be due to our institution being a tertiary center in
the Southeast where there is a larger AA population. A
report of uveitis prevalence in adults in the Southeastern
US in 1997 demonstrated that of 385 patients, 31 % were
African American which is also of increased frequency
[40]. Focusing on regions with diverse populations could
help us better appreciate the differences in outcomes as-
sociated with race, and our results suggests the need for
further evaluation.
We were unable to make conclusions on the role of
Hispanic ethnicity since non-English speaking patients
were excluded. However, we have translated all ourinstruments and are actively recruiting children from
this population.
Conclusions
In conclusion, our results confirm age at JIA diagnosis
and the oligoarticular JIA subtype as predictors of uveitis
development, but we were unable to confirm predictors
of severe disease. We demonstrate that visual disability
may be underestimated in JIA outcome studies since few
studies look at vision specific QOL and function in chil-
dren with uveitis. Vision specific measures may reveal
areas of vision that are not quantified by general mea-
sures or the ocular exam. A comprehensive assessment
of disability that incorporates uveitis specific measures
may be a more clinically sensitive assessment of visual
outcome.
Our study also highlights the potential role of race in
uveitis and the need for further exploration in a large ra-
cially diverse cohort, likely in a multi-center study. Iden-
tifying high risk children will enable early, aggressive
treatment and potentially prevent visual complications
associated with severe disease.
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